Stay Ahead in Fast-Growing Economies.

Browse Reports Now

Anosmia Market – Latest Advancement & Future Trends (2024-2032)

In Stock
$3,090
In Stock

The Anosmia Market therefore can be described as the global market of general products for the treatment of anosmia, specific treatments to handle anosmia plus all diagnostic techniques handling anosmia which is linked with a reduced ability or loss of ability to smell. The market comprises pharma therapies for administering medications, a diagnostic kit, and therapeutic equipment for anosmia caused by viral infection, head trauma, nasal barriers, and neurological disorders.

Publication Date: 01/11/2025
Pages: 400
Region / Coverage: Global
In Stock
Country: Global
Product total
Options total
Grand total
Add to wishlist
IMR Group
Publisher:

IMR Group

Tag:

Description

Anosmia Market Synopsis:

Anosmia Market Size Was Valued at USD 3.04 Billion in 2023, and is Projected to Reach USD 4.47 Billion by 2032, Growing at a CAGR of 4.37 % From 2024-2032.

The Anosmia Market therefore can be described as the global market of general products for the treatment of anosmia, specific treatments to handle anosmia plus all diagnostic techniques handling anosmia which is linked with a reduced ability or loss of ability to smell. The market comprises pharma therapies for administering medications, a diagnostic kit, and therapeutic equipment for anosmia caused by viral infection, head trauma, nasal barriers, and neurological disorders. The growth of the market is attributed to increased awareness of the disease, enhancement of diagnostic procedures, and progressive research in olfactory-related therapies.

The use of anosmia is progressively increasing across the globe because detections of anosmia are increasing worldwide, especially following covid 19 where anosmia was seen as a symptom of the virus. The fact that post-COVID anosmia is becoming more common is fostering increased mentions of diagnostics and therapeutic solutions for anosmia Consequently, the demand for new solutions is rising. Also, olfactory retraining therapies are advancing day by day New pharmacological therapies and surgery way to treat anosmia efficiently.

Chronic and severe anosmia diagnosis and treatment is increasingly important among patients. The working of knowledge-raising campaigns as well as the incorporation of anosmia screening into simple clinic checkups has significantly improved on early detection. Another type of support in the market is coming from the various research that is being done in the area of regenerative science, particularly in the area of neurology fixing degraded the olfactory sense in patients with Irreversible Anosmia. In addition to a tremendous amount of innovation and increasing healthcare spending, the Anosmia Market thus has a great opportunity for development in the forecast period.

Anosmia Market Trend Analysis:

Integration of AI and Olfactory Diagnostics

The changing diagnosis of anosmia using Artificial intelligence is a trend in the Anosmia Market. It is worthy of notice here that the diagnostic tools are being touted to help in enhancing the use of AI techniques to identify the pattern of olfactory disorders and their fundamental causes with even greater precision. These tools are being used to enhance the smell tests and to offer individualized treatment recommendations based on the profile of the patient.

Wearable mainly devices installed with olfactory sensors are exploded as advanced technologies for ruining the assessment of the smell and identifying the extent of anosmia in real -life time, so it provides ample chance to go for timely diagnosis and intervention.

Rising Focus on Post-COVID Anosmia Treatment

As for the COVID-19 impact on Anosmia, the enhanced usage frequency of such an expression afterward has brought many opportunities for growing the Anosmia market. Some patients have had permanent loss of their sense of smell as a consequence of “long COVID”, companies and governments have had to increase funding for reliable treatment.

As governments around the globe, healthcare facilities, and pharmaceutical industries continue to search for other targeted therapies for post-COVID anosmia patients, olfactory retraining programs and supportive care management explore effective treatment modalities for the patients. This is a no-brainer because the world is experiencing high incidences of loss of smell post-virus and this is an opportunity to fill that niche of post-viral anosmia management

Anosmia Market Segment Analysis:

The anosmia market is segmented on the basis of Cause, Treatment Therapy, Severity, and Region.

By cause, Viral infection segment is expected to dominate the market during the forecast period

The Viral Infection segment is expected to have the largest market share in the Anosmia market during the COVID period because COVID cases across the world have been resulting in anosmia along with other symptoms. Infectious diseases act on the olfactory epithelium resulting in transient or permanent anosmia. COVID-19 has brought attention to the need for particular therapies and testing for anosmia due to virus such as including research studies and grants.

Pharmaceutical companies and research laboratories are working for medicines against viral diseases, and steroidal and stem cell therapies for assaulting the Ministry of Health. The processes involved in the loss of smell gradually due to a virus also help in the fashioning of new treatments that target the segment connected with Viral Infection as a segment in the industry.

By Severity, the Head trauma segment is expected to hold the largest share

The Head Trauma segment would be the largest of the Anosmia Market because TBI is a leading cause of anosmia. Head trauma almost always occurs in the region of the olfactory bulb or some other nerves that make up the sense of smell. This segment has been driven by the upsurge in the number of TBIs from road traffic injuries, sports as well as falls.

The therapy of patients with the loss of smell in connection with the traumas of the head implies the application of a complex of treatment and aesthetic operations, neurological consultations, and rehabilitation. Recent advancements in neuroimaging and regenerative medicine technology is providing new approaches to managing the anosmia caused due to head injuries and, thus, is a boon to this segment of the market.

Anosmia Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

The region is leading due to the presence a greater number of patient diagnosed with anosmia, a well-developed health care system, and good establishments in terms of R&D. In the United States, anosmia has become one of the most important symptoms associated with COVID-19 infection, which prompted the use of diagnostic and therapeutic technologies. However, advancement in government facilitating and spending in the rehabilitation programs after COVID has further invested in the market.

Canada too is participating in the region’s market domination, and understanding of anosmia, and the availability to diagnostic techniques and treatments has to be improved. The engaging activity of more strategic participants in the pharmaceutical and biotechnology industries of North America is one more factor that is stimulating market growth. In addition, the focus on innovation and increased proportion of tailored medication outcomes in North America retains its position as the leading region in the global Anosmia Market.

Active Key Playes in the Anosmia Market:

AbbVie Inc. (USA)

Alkem Laboratories Ltd. (India)

Amgen Inc. (USA)

AstraZeneca plc (UK)

Biogen Inc. (USA)

Cipla Inc. (India)

Eli Lilly and Company (USA)

F. Hoffmann-La Roche Ltd. (Switzerland)

GlaxoSmithKline plc (UK)

Merck & Co., Inc. (USA)

Novartis AG (Switzerland)

Pfizer Inc. (USA)

Regeneron Pharmaceuticals, Inc. (USA)

Sanofi (France)

Teva Pharmaceutical Industries Ltd. (Israel), and Other Active Players

Chapter 1: Introduction

 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape

 3.1 Market Dynamics

  3.1.1 Drivers

  3.1.2 Restraints

  3.1.3 Opportunities

  3.1.4 Challenges

 3.2 Market Trend Analysis

 3.3 PESTLE Analysis

 3.4 Porter’s Five Forces Analysis

 3.5 Industry Value Chain Analysis

 3.6 Ecosystem

 3.7 Regulatory Landscape

 3.8 Price Trend Analysis

 3.9 Patent Analysis

 3.10 Technology Evolution

 3.11 Investment Pockets

 3.12 Import-Export Analysis

Chapter 4: Anosmia Market by Cause

 4.1 Anosmia Market Snapshot and Growth Engine

 4.2 Anosmia Market Overview

 4.3 Viral infection

  4.3.1 Introduction and Market Overview

  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)

  4.3.3 Key Market Trends, Growth Factors and Opportunities

  4.3.4 Viral infection: Geographic Segmentation Analysis

 4.4 Head trauma

  4.4.1 Introduction and Market Overview

  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)

  4.4.3 Key Market Trends, Growth Factors and Opportunities

  4.4.4 Head trauma: Geographic Segmentation Analysis

 4.5 Nasal polyps

  4.5.1 Introduction and Market Overview

  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)

  4.5.3 Key Market Trends, Growth Factors and Opportunities

  4.5.4 Nasal polyps: Geographic Segmentation Analysis

 4.6 Neurological disorders

  4.6.1 Introduction and Market Overview

  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)

  4.6.3 Key Market Trends, Growth Factors and Opportunities

  4.6.4 Neurological disorders: Geographic Segmentation Analysis

Chapter 5: Anosmia Market by Severity

 5.1 Anosmia Market Snapshot and Growth Engine

 5.2 Anosmia Market Overview

 5.3 Complete anosmia

  5.3.1 Introduction and Market Overview

  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)

  5.3.3 Key Market Trends, Growth Factors and Opportunities

  5.3.4 Complete anosmia: Geographic Segmentation Analysis

 5.4 Partial anosmia

  5.4.1 Introduction and Market Overview

  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)

  5.4.3 Key Market Trends, Growth Factors and Opportunities

  5.4.4 Partial anosmia: Geographic Segmentation Analysis

 5.5 HyposmiaTreatment

  5.5.1 Introduction and Market Overview

  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)

  5.5.3 Key Market Trends, Growth Factors and Opportunities

  5.5.4 HyposmiaTreatment: Geographic Segmentation Analysis

Chapter 6: Company Profiles and Competitive Analysis

 6.1 Competitive Landscape

  6.1.1 Competitive Benchmarking

  6.1.2 Anosmia Market Share by Manufacturer (2023)

  6.1.3 Industry BCG Matrix

  6.1.4 Heat Map Analysis

  6.1.5 Mergers and Acquisitions  

 6.2 ABBVIE INC. (USA)

  6.2.1 Company Overview

  6.2.2 Key Executives

  6.2.3 Company Snapshot

  6.2.4 Role of the Company in the Market

  6.2.5 Sustainability and Social Responsibility

  6.2.6 Operating Business Segments

  6.2.7 Product Portfolio

  6.2.8 Business Performance

  6.2.9 Key Strategic Moves and Recent Developments

  6.2.10 SWOT Analysis

 6.3 ALKEM LABORATORIES LTD. (INDIA)

 6.4 AMGEN INC. (USA)

 6.5 ASTRAZENECA PLC (UK)

 6.6 BIOGEN INC. (USA)

 6.7 CIPLA INC. (INDIA)

 6.8 ELI LILLY AND COMPANY (USA)

 6.9 F. HOFFMANN-LA ROCHE LTD. (SWITZERLAND)

 6.10 GLAXOSMITHKLINE PLC (UK)

 6.11 MERCK & CO. INC. (USA)

 6.12 NOVARTIS AG (SWITZERLAND)

 6.13 PFIZER INC. (USA)

 6.14 REGENERON PHARMACEUTICALS INC. (USA)

 6.15 SANOFI (FRANCE)

 6.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)

 6.17 OTHER ACTIVE PLAYERS

Chapter 7: Global Anosmia Market By Region

 7.1 Overview

 7.2. North America Anosmia Market

  7.2.1 Key Market Trends, Growth Factors and Opportunities

  7.2.2 Top Key Companies

  7.2.3 Historic and Forecasted Market Size by Segments

  7.2.4 Historic and Forecasted Market Size By Cause

  7.2.4.1 Viral infection

  7.2.4.2 Head trauma

  7.2.4.3 Nasal polyps

  7.2.4.4 Neurological disorders

  7.2.5 Historic and Forecasted Market Size By Severity

  7.2.5.1 Complete anosmia

  7.2.5.2 Partial anosmia

  7.2.5.3 HyposmiaTreatment

  7.2.6 Historic and Forecast Market Size by Country

  7.2.6.1 US

  7.2.6.2 Canada

  7.2.6.3 Mexico

 7.3. Eastern Europe Anosmia Market

  7.3.1 Key Market Trends, Growth Factors and Opportunities

  7.3.2 Top Key Companies

  7.3.3 Historic and Forecasted Market Size by Segments

  7.3.4 Historic and Forecasted Market Size By Cause

  7.3.4.1 Viral infection

  7.3.4.2 Head trauma

  7.3.4.3 Nasal polyps

  7.3.4.4 Neurological disorders

  7.3.5 Historic and Forecasted Market Size By Severity

  7.3.5.1 Complete anosmia

  7.3.5.2 Partial anosmia

  7.3.5.3 HyposmiaTreatment

  7.3.6 Historic and Forecast Market Size by Country

  7.3.6.1 Russia

  7.3.6.2 Bulgaria

  7.3.6.3 The Czech Republic

  7.3.6.4 Hungary

  7.3.6.5 Poland

  7.3.6.6 Romania

  7.3.6.7 Rest of Eastern Europe

 7.4. Western Europe Anosmia Market

  7.4.1 Key Market Trends, Growth Factors and Opportunities

  7.4.2 Top Key Companies

  7.4.3 Historic and Forecasted Market Size by Segments

  7.4.4 Historic and Forecasted Market Size By Cause

  7.4.4.1 Viral infection

  7.4.4.2 Head trauma

  7.4.4.3 Nasal polyps

  7.4.4.4 Neurological disorders

  7.4.5 Historic and Forecasted Market Size By Severity

  7.4.5.1 Complete anosmia

  7.4.5.2 Partial anosmia

  7.4.5.3 HyposmiaTreatment

  7.4.6 Historic and Forecast Market Size by Country

  7.4.6.1 Germany

  7.4.6.2 UK

  7.4.6.3 France

  7.4.6.4 The Netherlands

  7.4.6.5 Italy

  7.4.6.6 Spain

  7.4.6.7 Rest of Western Europe

 7.5. Asia Pacific Anosmia Market

  7.5.1 Key Market Trends, Growth Factors and Opportunities

  7.5.2 Top Key Companies

  7.5.3 Historic and Forecasted Market Size by Segments

  7.5.4 Historic and Forecasted Market Size By Cause

  7.5.4.1 Viral infection

  7.5.4.2 Head trauma

  7.5.4.3 Nasal polyps

  7.5.4.4 Neurological disorders

  7.5.5 Historic and Forecasted Market Size By Severity

  7.5.5.1 Complete anosmia

  7.5.5.2 Partial anosmia

  7.5.5.3 HyposmiaTreatment

  7.5.6 Historic and Forecast Market Size by Country

  7.5.6.1 China

  7.5.6.2 India

  7.5.6.3 Japan

  7.5.6.4 South Korea

  7.5.6.5 Malaysia

  7.5.6.6 Thailand

  7.5.6.7 Vietnam

  7.5.6.8 The Philippines

  7.5.6.9 Australia

  7.5.6.10 New Zealand

  7.5.6.11 Rest of APAC

 7.6. Middle East & Africa Anosmia Market

  7.6.1 Key Market Trends, Growth Factors and Opportunities

  7.6.2 Top Key Companies

  7.6.3 Historic and Forecasted Market Size by Segments

  7.6.4 Historic and Forecasted Market Size By Cause

  7.6.4.1 Viral infection

  7.6.4.2 Head trauma

  7.6.4.3 Nasal polyps

  7.6.4.4 Neurological disorders

  7.6.5 Historic and Forecasted Market Size By Severity

  7.6.5.1 Complete anosmia

  7.6.5.2 Partial anosmia

  7.6.5.3 HyposmiaTreatment

  7.6.6 Historic and Forecast Market Size by Country

  7.6.6.1 Turkiye

  7.6.6.2 Bahrain

  7.6.6.3 Kuwait

  7.6.6.4 Saudi Arabia

  7.6.6.5 Qatar

  7.6.6.6 UAE

  7.6.6.7 Israel

  7.6.6.8 South Africa

 7.7. South America Anosmia Market

  7.7.1 Key Market Trends, Growth Factors and Opportunities

  7.7.2 Top Key Companies

  7.7.3 Historic and Forecasted Market Size by Segments

  7.7.4 Historic and Forecasted Market Size By Cause

  7.7.4.1 Viral infection

  7.7.4.2 Head trauma

  7.7.4.3 Nasal polyps

  7.7.4.4 Neurological disorders

  7.7.5 Historic and Forecasted Market Size By Severity

  7.7.5.1 Complete anosmia

  7.7.5.2 Partial anosmia

  7.7.5.3 HyposmiaTreatment

  7.7.6 Historic and Forecast Market Size by Country

  7.7.6.1 Brazil

  7.7.6.2 Argentina

  7.7.6.3 Rest of SA

Chapter 8 Analyst Viewpoint and Conclusion

8.1 Recommendations and Concluding Analysis

8.2 Potential Market Strategies

Chapter 9 Research Methodology

9.1 Research Process

9.2 Primary Research

9.3 Secondary Research

Q1: What would be the forecast period in the Anosmia Market research report?

A1: The forecast period in the Anosmia Market research report is 2024-2032.

Q2: Who are the key players in the Anosmia Market?

A2: AbbVie Inc. (USA), Alkem Laboratories Ltd. (India), Amgen Inc. (USA), AstraZeneca plc (UK), Biogen Inc. (USA), Cipla Inc. (India), Eli Lilly and Company (USA), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (UK), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Pfizer Inc. (USA), Regeneron Pharmaceuticals, Inc. (USA), Sanofi (France), Teva Pharmaceutical Industries Ltd. (Israel), and Other Active Players

Q3: What are the segments of the Anosmia Market?

A3: The Anosmia Market is segmented into Cause, Treatment therapy, Severity, and region. By Cause, the market is categorized into Viral infection, Head trauma, Nasal polyps, and Neurological disorders. By Severity, the market is categorized into Complete anosmia, Partial anosmia, and Hyposmia. By Treatment therapy, the market is categorized into medical therapy, Surgical intervention, and Olfactory retraining. By region, it is analyzed across North America (U.S., Canada, Mexico), Eastern Europe (Russia, Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe), Western Europe (Germany, UK, France, Netherlands, Italy, Spain, Rest of Western Europe), Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC), Middle East & Africa (Turkiye, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa), South America (Brazil, Argentina, Rest of SA).

Q4: What is the Anosmia Market?

A4: The Anosmia Market therefore can be described as the global market of general products for the treatment of anosmia, specific treatments to handle anosmia plus all diagnostic techniques handling anosmia which is linked with a reduced ability or loss of ability to smell. The market comprises pharma therapies for administering medications, a diagnostic kit, and therapeutic equipment for anosmia caused by viral infection, head trauma, nasal barriers, and neurological disorders. The growth of the market is attributed to increased awareness of the disease, enhancement of diagnostic procedures, and progressive research in olfactory-related therapies.

Q5: How big is the Anosmia Market?

A5: Anosmia Market Size Was Valued at USD 3.04 Billion in 2023, and is Projected to Reach USD 4.47 Billion by 2032, Growing at a CAGR of 4.37 % From 2024-2032.

How to Buy a Report from eminsights.jp

On the product page, choose the license you want: Single-User License, Multi-User License or Enterprise License.

If you required report in your native language, then you can click on Translated Report button and fill out the form with report name and language you want, then our team will contact you as soon as possible.

Click the Buy Now button.

You will be redirected to the checkout page. Enter your company details and payment information.

Click Place Order to complete the purchase.

Confirmation: You’ll receive an order confirmation and our team will contact you shortly with your ordered report.

If you have any questions, fill out the contact form below or email us at bizdev@eminsights.net.

Thank you for choosing eminsights.jp!